Eledon Pharma's Tegoprubart Receives FDA Orphan Drug Designation for Liver Transplantation

Eledon Pharmaceuticals' tegoprubart has been granted orphan drug designation by the FDA for preventing allograft rejection in liver transplantation. The drug has previously received orphan drug status for pancreatic islet cell transplantation and amyotrophic lateral sclerosis treatment. The company plans to evaluate tegoprubart's potential in a clinical trial starting later this year.